Functionalization of polymeric nanoparticles with targeting VNAR ligands using vinyl sulfone conjugation

Leach, Adam; Finnegan, Marie; Machado, Mariana Stefani; Ferguson, Laura; Steven, John; Smyth, P. P. A.; Porter, Andrew; Barelle, Caroline; Themistou, Efrosyni; Scott, Christopher J.

doi:10.1039/d2tb01985j

Cited by 2 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, equivalent free dexamethasone had no discernible effect. Furthermore, single-domain Variable New Antigen Receptors (VNARs) derived from sharks and cartilaginous fish have been engineered into novel NDCs by conjugating with diverse agents [ 50 , 51 ]. Remarkably, VNAR-Fc MMAE conjugates demonstrated remarkably sub-nanomolar potency against lymphoma [ 52 ].…”

Section: Based On Single-domain Antibodiesmentioning

confidence: 99%

Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

Ma,

Wang,

Ying

et al. 2024

Antibody Therapeutics

View full text Add to dashboard Cite

In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. However, realization of the maximum clinical use of ADCs requires surmounting extant challenges, mainly the limitations in tumor penetration capabilities when targeting solid tumors. To resolve the hurdle of suboptimal tumor penetration, miniaturized antibody fragments with engineered formats have been harnessed for ADC assembly. By virtue of their reduced molecular sizes, antibody fragment-drug conjugates (FDCs) hold considerable promise for efficacious delivery of cytotoxic agents, thus conferring superior therapeutic outcomes. This review will focus on current advancements in novel ADC development utilizing smaller antibody formats from approximately 6 to 80 kDa, with particular emphasis on single-domain antibodies, which have been widely applied in novel ADC design. Additionally, strategies to optimize clinical translation are discussed, including half-life extension, acceleration of internalization, and reduction of immunogenic potential.

show abstract

Section: Based On Single-domain Antibodiesmentioning

confidence: 99%

Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

Ma,

Wang,

Ying

et al. 2024

Antibody Therapeutics

View full text Add to dashboard Cite

show abstract

Surface Bio‐engineered Polymeric Nanoparticles

Haidar,

Bilek,

Akhavan

2024

Small

View full text Add to dashboard Cite

Surface bio‐engineering of polymeric nanoparticles (PNPs) has emerged as a cornerstone in contemporary biomedical research, presenting a transformative avenue that can revolutionize diagnostics, therapies, and drug delivery systems. The approach involves integrating bioactive elements on the surfaces of PNPs, aiming to provide them with functionalities to enable precise, targeted, and favorable interactions with biological components within cellular environments. However, the full potential of surface bio‐engineered PNPs in biomedicine is hampered by obstacles, including precise control over surface modifications, stability in biological environments, and lasting targeted interactions with cells or tissues. Concerns like scalability, reproducibility, and long‐term safety also impede translation to clinical practice. In this review, these challenges in the context of recent breakthroughs in developing surface‐biofunctionalized PNPs for various applications, from biosensing and bioimaging to targeted delivery of therapeutics are discussed. Particular attention is given to bonding mechanisms that underlie the attachment of bioactive moieties to PNP surfaces. The stability and efficacy of surface‐bioengineered PNPs are critically reviewed in disease detection, diagnostics, and treatment, both in vitro and in vivo settings. Insights into existing challenges and limitations impeding progress are provided, and a forward‐looking discussion on the field's future is presented. The paper concludes with recommendations to accelerate the clinical translation of surface bio‐engineered PNPs.

show abstract

Functionalization of polymeric nanoparticles with targeting VNAR ligands using vinyl sulfone conjugation

Abstract: Actively targeted drug loaded nanoparticles represent an exciting new form of therapeutics for cancer and other diseases. These formulations are complex and in order to realize their ultimate potential, optimization...

Cited by 2 publications

References 43 publications

Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

Surface Bio‐engineered Polymeric Nanoparticles

Contact Info

Product

Resources

About